Ravinder Singh
Associate Professor and Head Clinical Studies at Chitkara College of Pharmacy, Chitkara University, Punjab, India
Title: Open Labelled Randomised Parallel Clinical Study: Evaluation of Bgr-34 And Sitagliptin in Diabetic Patients.
Biography
Biography: Ravinder Singh
Abstract
This study concerns in the simultaneous open model clinical study of the drug named sitagliptin a potent hyperglycaemic drug against a novel entity of natural origin BGR-34 in diabetic subjects. This study comprises the randomized, parallel, comparative study in which 100 subjects were planned to include. The patients were randomly divided in two groups on the basis of Inclusion and Exclusion criteria. Total 90 patients of mean age 30-65 years with type 2 diabetes were enrolled in this study and then the data was analysed on the basis of the different test which included HbA1c (glycated haemoglobin), rbs (random blood sugar), fbs (fasting blood sugar) and ppg (postprandial glucose) values. After completion of the data calibration results were analyzed and as a result 10-20% decreased values of HBA1C values accompanied with the RBS, FBS and PPG values were seen with the patients undergoing with 12 week course of the BGR-34. The results concluded that BGR-34 is effective in the reducing high blood sugar levels and this reflects that BGR-34 therapy is more effective drug in the treatment of diabetes suggesting that it is better in efficacy, reliability and affordability with little or no adverse effects.